Wells Fargo Maintains Overweight on NeuroPace, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Vik Chopra maintains an Overweight rating on NeuroPace (NASDAQ:NPCE) but lowers the price target from $20 to $15.
August 14, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo analyst Vik Chopra maintains an Overweight rating on NeuroPace but lowers the price target from $20 to $15.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns about future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100